Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

ter, Genzyme

generated approximately $373 million in cash from net income prior to

one-time events and proceeds from the issuance of common stock. The

company invested approximately $122 million in capital projects to

expand manufacturing capacity to meet current and anticipated product

demand. The company also made a $150 million investment in Isis

Pharmaceuticals associated with the license of mipomersen, a highly

promising product candidate in late-stage development.

-- Genzyme is also using a portion of its operating cash flow to

repurchase shares under a three-year program to reduce the dilutive

effect of equity compensation. The company repurchased 1 million

shares in the first quarter and has repurchased approximately 4.5

million shares since this program began one year ago.

"We had a very strong first quarter to start the year," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "We continue to focus on our commitment to deliver 20 percent non-GAAP earnings growth through 2011, while building the company to ensure that we sustain our growth over the longer term."

Financial Guidance

-- Genzyme expects 2008 non-GAAP earnings of approximately $3.90 per

diluted share, compared with prior guidance of $4.00 per diluted share.

This previously announced adjustment reflects the delay in FDA approval

of 2000L production capacity for Myozyme.

-- GAAP earnings in 2008 are expected to be approximately $2.65 per

diluted share, compared with prior guidance of approximately $2.75 per

diluted share. GAAP figures include anticipated amortization and

stock-compensation expenses and the effect of contingent convertible

debt.

-- Genzyme reaffirmed its commitment to 20 percent growth in compound non-

GAAP earnings per share through 2011. No
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and NEW YORK CITY ... -- As a leading provider of market research reports and ... Worldwide, LLC, indicating that 2015 will be a year of ... For executives operating a stem cell company or cord ... difficult task. You must analyze market conditions, predict industry trends, ...
(Date:4/1/2015)... Parsippany, NJ (PRWEB) April 01, 2015 ... joined BioNJ, a vibrant life sciences industry association that ... over 400 members. , Jonathan Parker, AJO’s Vice ... Annual Gala Dinner in February, an event that attracted ... evening’s highlights, Don Wright, a 73 year old cancer ...
(Date:4/1/2015)... April 1, 2015 Immunocore ... novel biological drugs to treat cancer, viral infections ... the appointment of Christina Coughlin as ... for providing medical and regulatory leadership to the ... Dr. Coughlin has extensive experience in oncology ...
(Date:3/31/2015)... March 31, 2015  Biotest Pharmaceuticals Corporation (BPC), a ... announce the addition of its newest plasma collection center ... Conway, Arkansas . The over 16,000 square ... on March 26 th 2015 and brings the ... "This facility represents another milestone in ...
Breaking Biology Technology:MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4Biotest Pharmaceuticals Corporation Announces the Opening of its Newest Plasma Collection Facility in Conway, Arkansas 2
... , ... --,China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; ,China ... of pharmaceuticals in Northeastern China, today announced it has,completed ... List. , The Chinese government ...
... , NOVATO, Calif., Nov. 30 BioMarin Pharmaceutical Inc. ... and Drug Administration (FDA) has granted orphan drug designation ... disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has ... Also, in October 2009, the Committee for Medicinal Products ...
... , SEATTLE, ... MTA: CTIC) announced today that its new class of ... potency and activity compared to currently available platinum-based compounds ... cancer cell lines. The results were presented in ...
Cached Biology Technology:China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the addition ... report to their offering. This report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2013 ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... is the liquid elixir that nurtures the growth of billions ... ample supply of water for farming and agriculture often means ... world, however, suffer from the opposite - the growing scarcity ... drought and desertification to climate change and climate variability, pollution, ...
... DC Scientists at the Lombardi Comprehensive Cancer Center at ... million grant to tease apart in the most comprehensive ... in breast cells in cancer development and treatment. This protein ... breast cancer and how she will fare during her treatment. ...
... 22nd, 2010-Riparian areas, ecosystems caught between the land ... temporal variability. Effectively managing and protecting riparian areas ... concepts. Fortunately, scientists are investigating new approaches in ... One of those approaches is photography. By taking ...
Cached Biology News:More water for life 2More water for life 3Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3Learning about riparian areas from photographs 2
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Complete cell culture media with cytokines...
Biology Products: